MARKET

MDWD

MDWD

Mediwound
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.530
-0.040
-0.88%
Opening 12:09 06/16 EDT
OPEN
4.550
PREV CLOSE
4.570
HIGH
4.590
LOW
4.500
VOLUME
50.21K
TURNOVER
--
52 WEEK HIGH
6.07
52 WEEK LOW
1.980
MARKET CAP
123.42M
P/E (TTM)
-12.7534
1D
5D
1M
3M
1Y
5Y
BRIEF-Mediwound Completes Patient Enrollment For Interim Assessment Of Its U.S. Escharex Phase 2 Adaptive Design Study
reuters.com · 6d ago
MediWound completes enrollment for interim assessment of mid-stage EscharEx study
MediWound (MDWD) completes patient enrollment for the interim assessment of its U.S. EscharEx Phase 2 study for the treatment of venous leg ulcers ((VLUs)).The company said that the interim assessment,
Seekingalpha · 6d ago
MediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design Study
MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that the enrollment target of patients for an interim assessment of its Esch...
GlobeNewswire · 6d ago
MediWound Hits Patient Enrollment Target for Interim Assessment Related to Phase 2 Study of Venous Leg Ulcers
MT Newswires · 6d ago
What Is The Ownership Structure Like For MediWound Ltd. (NASDAQ:MDWD)?
A look at the shareholders of MediWound Ltd. ( NASDAQ:MDWD ) can tell us which group is most powerful. Insiders often...
Simply Wall St. · 06/09 08:34
BRIEF-MediWound Announces Peer-Reviewed Paper Of A Case Series Report Of Basal Cell Carcinoma Published In Open Dermatology Journal
reuters.com · 06/07 11:28
MediWound Announces Peer-Reviewed Paper of a Case Series Report of Basal Cell Carcinoma Published in the Open Dermatology Journal
Findings Provide Preliminary Proof-of-Concept Phase I/II Clinical Study in Basal Cell Carcinoma Scheduled to Begin in Second Quarter 2021, with Data Expected by the End of 2021 YAVNE, Israel, June 07, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD),...
GlobeNewswire · 06/07 11:00
Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates
The FDA review machinery worked overtime in May, completing reviews of several drug applications. Except for stray rejections or delays, the agency churned out mostly positive outcomes.
Benzinga · 06/01 21:31
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MDWD. Analyze the recent business situations of Mediwound through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MDWD stock price target is 7.50 with a high estimate of 10.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 40
Institutional Holdings: 5.24M
% Owned: 19.25%
Shares Outstanding: 27.25M
TypeInstitutionsShares
Increased
12
208.43K
New
6
762.28K
Decreased
4
739.00K
Sold Out
7
174.89K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.28%
Pharmaceuticals & Medical Research
+0.13%
Key Executives
Chairman/Independent Director
Stephen Wills
Chairman/Executive Director
stephen Wills
Chief Executive Officer
Sharon Malka
Chief Executive Officer
Cal Cohen
Chief Financial Officer
Boaz Gur-Lavie
Executive Vice President/General Counsel/Secretary
Yaron Meyer
Chief Technology Officer
Lior Rosenberg
Other
Ety Klinger
Director
David Fox
Director
Ofer Gonen
Director
Samuel Moed
Director
Assaf Segal
Independent Director
Vickie Driver
Independent Director
Sharon Kochan
Independent Director
Nissim Mashiach
No Data
About MDWD
MediWound Ltd. is a Israel-based biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.

Webull offers kinds of Mediwound Ltd stock information, including NASDAQ:MDWD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDWD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MDWD stock methods without spending real money on the virtual paper trading platform.